Rhinomed Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was AUD 9.1 million compared to AUD 3.89 million a year ago. Net loss was AUD 5.28 million compared to AUD 8.64 million a year ago.

Basic loss per share from continuing operations was AUD 0.0202 compared to AUD 0.034 a year ago. Diluted loss per share from continuing operations was AUD 0.0202 compared to AUD 0.034 a year ago.